bioAffinity Technologies holds special stockholder meeting
BIAF•bioAffinity Technologies shareholders approved reducing authorized common shares from 350 million to 200 million and authorized issuances under August and October warrants and in non-public offerings at a November 20, 2026, special meeting.
1. Shareholders approve proposals
At the November 20, 2026, special meeting, shareholders approved reducing authorized common shares from 350 million to 200 million. The charter amendment became effective immediately upon filing that day. Shareholders also authorized issuing up to 1,128,272 common shares under August warrants and 980,072 under October warrants, as well as securities in one or more non-public offerings. An adjournment to solicit additional proxies was approved but was unnecessary because all other proposals passed.




